NEXT BIOTECH

ACW Starts Phase II Clinical Trials: Major Milestone Set to Unlock Value Uplift?

Next Investors Archived Aug 24, 2016

There are currently an estimated 50 million suffers of Alzheimer’s disease (AD) globally, the highest rate in history. The consequent costs on healthcare providers are enormous and growing.

DXB Close to Phase 2 Results: Progresses Promising CKD Product

Next Investors Archived Aug 16, 2016

Dimerix (ASX:DXB) has just completed its “pre-IND” consultation with US regulatory body the Food and Drug Administration (FDA) with some encouraging outcomes reported. The big news for DXB is that its intended Phase 3 DMX-200 trial will be positioned as an adjunct therapy and not a fixed dose combination therapy.

New ASX Listing to Turbo Charge Treatment in $100BN Oncology Market

Next Investors Archived Aug 09, 2016

The weird and wonderful world of Biotechnology has a lot going for it — an industry working at the sharp-end of breakthrough medical research, Biotech is also one of the more enticing investment landscapes of modern times. In how many other industries are companies literally striving to save lives?

Medical Cannabis Stock MXC Approaching Revenue Uplift?

Next Investors Archived Jul 22, 2016

Having gained regulatory approval to sell its MGC Derma Anti-Aging line of Cannabidiol-based cosmetic products in the US, MGC Pharmaceuticals (ASX:MXC) recently received its first revenues under its exclusive Californian distribution deal. The first year of the deal is expected to net MXC approximately AU$1.76M – a substantial number for this $51.5M capped company that has only really been on the ASX boards for a short amount of time.

US Sales Unlocked for CDY: Pathway to $100M Revenue in Near Term

Next Investors Archived Jul 20, 2016

After generating strong sales figures across Japan and Australia for its hair loss product evolis®, Cellmid (ASX:CDY) has now taken its first step in cracking the major US market. The global hair loss market is estimated to be around US$7BN annually, with topical treatments accounting for $2.3 billion of that market.

New ASX Listing: $15M Capped Stock with Phase II Trialled Cancer Drug

Next Investors Archived Jul 19, 2016

One of the latest stocks to list on the ASX happens to have a very small market cap, but a very advanced oncology drug with early sales potential. This $15M capped stock just raised $4M as part of its entry to the ASX, and its inherent value is in a niche cancer drug named Bisantrene that was ‘lost’ in the 1990s – buried under the weight of so-called billion-dollar blockbuster drugs that better suit Big Pharma’s margins.

MMJ Now Licensed to Grow Medical Cannabis

Next Investors Archived Jul 05, 2016

There are just 32 companies in Canada that have a license to grow medical cannabis – and MMJ PhytoTech, Ltd (ASX:MMJ) has just officially joined their ranks – the first ASX listed company to do so. A licence to grow medicinal cannabis is not easy to get your hands on in Canada – over 1200 companies have tried, and over 1000 have failed or given up – indicating the stringent nature of the country’s health regulators.

$26M Capped ASX Stock Generating Millions in Revenue: US and Chinese Markets are Next

Next Investors Archived Jun 14, 2016

With a total global market of $90 billion, successful hair loss products can generate hundreds of millions of dollars in revenue. However the current market leaders may soon be under pressure from one particular ASX listed life sciences company.

Multi-Billion Alzheimer’s Drug Development Boom Underway: ACW Well Positioned in Phase II Trials

Next Investors Archived Jun 08, 2016

Prominent US financial institution JP Morgan recently released a rather bullish report on Alzheimer’s disease – a sector they think represents one of the most attractive up and coming categories in biotech.

FDA Approval for MXC: Sales Doors Open in US, Euro and Canadian Markets

Next Investors Archived May 31, 2016

When the US Food and Drug Administration (FDA) gives companies its seal of approval, it usually signals the start of a fully endorsed, regulatory-approved push into large commercial markets. No matter what industry a company operates in, FDA product approval is a big milestone.

DXB to Hit Major Milestone: Early Phase II Results Due in Coming Weeks

Next Investors Archived May 25, 2016

Within the next quarter, $12M capped Dimerix (ASX:DXB) is due to publish early results from Phase II clinical trials of its flagship drug therapy DMX-200, a combination therapy designed to alleviate the suffering of people afflicted with Chronic Kidney Disease (CKD).

Medical Cannabis Player MXC Hits First Retail Sales in US$460BN Cosmetics Market

Next Investors Archived May 04, 2016

We’ve been highlighting the changing landscape in the medical cannabis industry for quite a while. Forgotten for decades, cannabis is coming back as a soft medicine as governments the world over reconsider draconian drug enforcement policy that in hindsight, was throwing the baby out with the bathwater.

Ex Pfizer VP to Repeat Market Topping Drug Development with this ASX Stock?

Next Investors Archived Apr 20, 2016

As humans continue to live longer, certain diseases start to become more apparent, causing widespread concern for the elderly and their families. One of them is Alzheimer’s disease (AD) – a horrific disease that starts off with short-term memory loss and gradually progresses to severe memory failure including forgetting your own children and family.

MMJ Set to Boost Medical Cannabis Production Capacity by 1000%?

Next Investors Archived Apr 01, 2016

The market for medical cannabis is gradually moving out of the wilderness and onto government radars. The once forgotten medicine is currently being re-evaluated and reclassified in the US, Australia and Europe as its positive effect on a range of ailments is finally being rediscovered and decriminalised by governments across the globe.

Next Biotech